<Page>

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

SCHEDULE 14C

INFORMATION STATEMENT PURSUANT TO SECTION 14(C)
OF THE SECURITIES EXCHANGE ACT OF 1934

Check the appropriate box:

/ / Preliminary Information Statement
/ / Confidential, For Use of the Commission Only (as permitted by Rule
14c-5(d)(2))
/X/ Definitive Information Statement

Diamond Entertainment Corporation
(Name of Registrant As Specified In Charter)

Not Applicable
(Name of Person(s) Filing the Information Statement if other than Registrant)

Payment of Filing Fee (Check the appropriate box):

/X/ No fee required.
/ / Fee computed on table below per Exchange Act Rules 14c-5(g) and 0-11.

1) Title of each class of securities to which transaction applies:

2) Aggregate number of securities to which transaction applies:

3) Per unit price or other underlying value of transaction computed pursuant
to Exchange Act Rule 0-11:

4) Proposed maximum aggregate value of transaction:

/ / Check box if any part of the fee is offset as provided by Exchange Act Rule
0-11(a)2) and identify the filing for which the offsetting fee was paid
previously. Identify the previous filing by registration statement number, or
the Form or Schedule and the date of its filing.

1) Amount Previously Paid:

2) Form, Schedule or Registration Statement No.:

3) Filing Party:

4) Date Filed:

<Page>

DIAMOND ENTERTAINMENT CORPORATION
18725 E. Gale Ave., Suite 100
City of Industry, CA 91748

NOTICE OF WRITTEN CONSENT OF SHAREHOLDERS

July 25, 2007

To Shareholders of Diamond Entertainment Corporation:

NOTICE IS HEREBY GIVEN that the following actions will be taken pursuant to the
written consent of a majority of our shareholders, dated June 30, 2007, in lieu
of a special meeting of the shareholders. The following actions will be
effective on or about August 14, 2007:

1. amend our certificate of incorporation to change the Company name
from Diamond Entertainment Corporation (The "Company") to Rx for
Africa, Inc.

2. the ratification of the appointment of Bernstein & Pinchuk, LLP as
our independent accountants for the current fiscal year.

3. To consider and transact such other business as may properly come
before the Meeting or any adjournment(s) thereof.

This Notice and the attached Information Statement are being circulated to
advise the shareholders of certain actions already approved by written consent
of the shareholders who collectively hold a majority of the voting power of our
common stock. Pursuant to Rule 14c-2 under the Securities Exchange Act of 1934,
as amended, the proposals will not be effective until 20 days after the date
this Information Statement is mailed to the shareholders. Therefore, this Notice
and the attached Information Statement are being sent to you for informational
purposes only.

By Order of the Board of Directors,
Dr. Mulugetta Bezzabeth

/s/ Dr. Mulugetta Bezzabeth
--------------------------------------
Dr. Mulugetta Bezzabeth, Chief
Executive Officer and Director.

<Page>

DIAMOND ENTERTAINMENT CORPORATION
18725 E. Gale Ave., Suite 100
City of Industry, CA 91748

INFORMATION STATEMENT
WRITTEN CONSENT OF SHAREHOLDERS

WE ARE NOT ASKING YOU FOR A PROXY
AND YOU ARE REQUESTED NOT TO SEND US A PROXY

This Information Statement is furnished in accordance with the requirements of
Regulation 14C promulgated under the Securities Exchange Act of 1934, as
amended, by Diamond Entertainment Corporation (the "Company")., a New Jersey
corporation, in connection with certain actions to be taken by the written
consent by the majority shareholders of Diamond Entertainment, dated June 30,
2007.

Pursuant to Rule 14c-2 under the Securities Exchange Act of 1934, as amended,
the actions will not be effective until 20 days after the date of this
Information Statement is mailed to the shareholders.

THE APPROXIMATE DATE OF MAILING OF THIS INFORMATION STATEMENT IS July 25, 2007.

We anticipate that the actions contemplated by this Information Statement will
be effected on or about the close of business on August 14, 2007.

The actions to be effective twenty days after the mailing of this Information
Statement are as follows:

1. amendment of our certificate of incorporation to change the Company
name from Diamond Entertainment, Corp. to Rx for Africa, Inc., and
concurrently to change the Company's OTCBB trading symbol.

2. the ratification of the appointment of Bernstein & Pinchuk, LLP as
our independent accountants for the current fiscal year.

3. To consider and transact such other business as may properly come
before the Meeting or any adjournment(s) thereof.

Shareholders of record at the close of business on June 30, 2007 are entitled to
notice of the action to be effective on or about August 13, 2007. As of the
record date, our authorized capitalization consisted of 800,000,000 shares of
common stock, no par value, of which 189,821,018 were issued and outstanding.
Each share of our common stock entitles its holder to one vote on each matter
submitted to the shareholders. However, because the shareholders holding at
least a majority of the voting rights of all outstanding shares of capital stock
as of the record date have voted in favor of the foregoing actions by resolution
dated June 30, 2007; and having sufficient voting power to approve such
proposals through their ownership of the capital stock, no other consents will
be solicited in connection with this Information Statement.

This Information Statement will serve as written notice to shareholders pursuant
to Title 14A:5-6 Corporations, General, of the New Jersey Permanent Statutes.

<Page>

SHAREHOLDER DISSENTER'S RIGHT OF APPRAISAL

The Title 14A, Chapter 11, Corporations, General, of the New Jersey Permanent
Statutes, does not provide for dissenter's rights of appraisal in connection
with the proposed actions.

THIS IS NOT A NOTICE OF A SPECIAL MEETING OF SHAREHOLDERS AND NO SHAREHOLDER
MEETING WILL BE HELD TO CONSIDER ANY MATTER WHICH WILL BE DESCRIBED IN THIS
INFORMATION STATEMENT.

Voting Securities and Principal Holders Thereof

As of the Record Date, there were 189,821,018 common shares outstanding.
The Common Stock constitutes the outstanding class of voting securities of
Diamond Entertainment Corporation. The shares have been considered fully
diluted, for a total amount of 189,821,018 shares used for purposes of the
ownership percentage calculations. Each share entitles the holder to one (1)
vote on all matters submitted to shareholders.

Shareholders representing over 51.0% of the votes of the currently issued
and outstanding shares of Common Stock have executed the Written Consents,
thereby ensuring the stock combination. See "Other Information Regarding The
Company - Security Ownership of Certain Beneficial Owners and Management."

Set forth below is a table of the stockholders who have executed the Written
Consents and, to the best of the Company's knowledge, the number of shares of
Common Stock beneficially owned by such stockholders as of April 15, 2007:

Total Common Issued and Outstanding: 189,821,018
Votes Possible: 189,821,018
Votes by Written Consent See below

Beneficial Owner Common Shares Votes in Favor % of Total Votes
- ---------------- ------------- -------------- ----------------

Mulugetta Bezzabeth 85,269,000 85,269,000 47,0%
Margie Chassman 58,336,437 58,336,437 30.7%

Total 143,605,437 143,605,437 77.7%

<Page>

OTHER INFORMATION REGARDING THE COMPANY

ABOUT DIAMOND ENTERTAINMENT CORPORATION

On May 4, 2007, Diamond Entertainment Corporation's wholly owned subsidiary,
Diamond Entertainment Acquisition, Inc., acquired Rx for Africa, Inc. through a
merger of a subsidiary of DMON. Rx Africa (Ethiopia) PLC, a subsidiary of Rx for
Africa, Inc., owns and operates a state-of-the art pharmaceutical plant built on
twenty three thousand square meters of land located south of Addis Ababa,
Ethiopia. The facility was established to manufacture HIV/AIDS, malaria,
tuberculosis and other generic drugs for distribution initially in Ethiopia and
eventually throughout Africa. The company is currently producing and marketing a
total of six products, and is in the process of scaling up its production with
the expectation of producing at least 30 new products by late 2007

STOCK OWNERSHIP

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS

The following table sets forth certain information known to the Company with
respect to the beneficial ownership of the Company's common stock as of June 30,
2007 by (i) each person who is known by the Company to own beneficially more
than 5% of the Company's common stock, (ii) each of the Company's directors and
executive officers, and (iii) all officers and directors of the Company as a
group.

Name and Address (1) Common Stock Preferred Shares Adjusted
Owned Percent of Class converted (2) Percent of Class (3)
- ------------------------------------------------------------------------------------------------------------------------

James K.T. Lu (4) 1,178,493 0.62% 13,603 0.63%
800 Tucker Lane
Walnut, CA 91768
- ------------------------------------------------------------------------------------------------------------------------

Fred U. Odaka (5) 111,111 0.06%
800 Tucker Lane
Walnut, CA 91789
- ------------------------------------------------------------------------------------------------------------------------

Mulugetta Bezzabeth (6) 85,269,000 44.92%
c/c Andrew Levinson
Greenberg & Hahr
230 Park Avenue, Suite 430
New York, NY 10169
- ------------------------------------------------------------------------------------------------------------------------

Margie Chassman 58,336,437 30.73%
445 W. 23rd Street, #16E
New York, NY 10011
- ------------------------------------------------------------------------------------------------------------------------

All current directors and
Executive Officers
(Group of 3) 86,558,604 45.29% 13,603 .063%
- ------------------------------------------------------------------------------------------------------------------------

<Page>

(1) Beneficial Ownership is determined in accordance with the rules of the
Securities and Exchange Commission and generally includes voting or investment
power with respect to securities. Shares of common stock subject to options or
warrants currently exercisable or convertible, or exercisable or convertible
within 60 days of August 31, 2005 are deemed outstanding for computing the
percentage of the person holding such option or warrant but are not deemed
outstanding for computing the percentage of any other person. Except as pursuant
to applicable community property laws, the persons named in the table have sole
voting and investment power with respect to all shares of common stock
beneficially owned.

(2) The preferred stock entitles the holder to 1.95 votes for each share owned
and each share may be converted into 1.95 shares of common stock.

(3) Assumes conversion of the preferred shares.

(4) Mr. Lu is a director. Includes 555,556 shares of common stock issuable upon
exercise of warrants and options.

(5) Mr. Odaka is CFO. Includes 111,111 shares of common stock issuable upon
exercise of warrants and options.

(6) Mr. Bezzabeth is CEO and Director.

(7) Shares of common stock outstanding at 6-30-07 are 189,821,018 shares.

DIRECTORS AND EXECUTIVE OFFICERS

The Company's current officers and directors consist of the following persons:

Name Age Position with Company
---- --- ---------------------

Mulugetta Bezzabeh (1) 64 Chief Executive Officer and Director

Howard Becker (1) 48 Director

James K.T. Lu. (2) 59 Director

Fred U. Odaka. (3) 70 Chief Financial Officer

(1) Appointed April 26, 2007
(2) Resigned as President and Co-CEO on April 26, 2007
(3) Resigned as a Director on April 26, 2007

Dr. MULUGETTA BEZZABEH is currently the President and CEO of Rx for Africa
(Ethiopia) PLC, which he had founded in 2003 as Sunshine Pharmaceuticals. He was
appointed Director and CEO of Diamond Entertainment Corporation on April 30,
2007. Rx for Africa is a manufacturer and distributor of generic pharmaceuticals
and has been in a joint venture with the People's Republic of China. A factory
was built and production has commenced in generic anti-malarial and other
pharmaceuticals. In 2006, the Chinese were bought out by private interests, with
the goal of becoming one of the few FDA-GMP (Good Manufacturing
Practices)-approved pharmaceutical factories in Sub-Saharan Africa. Dr. Bezzabeh
was awarded his PhD from the University of Leeds in the UK. He began his career
as the Minister for Rural Development in Ethiopia.

HOWARD BECKER was elected as a Director of the Company on April 26, 2007. Mr.
Becker is also currently serving as Acting Chief Executive Officer and Director
of CepTor Corporation (OTC BB: CEPO), a publicly traded, development stage
biopharmaceutical company headquartered in New York City. Before joining CepTor
in December 2006, Mr. Becker was Vice President of Operations of Xechem
International, Inc. (OTC BB: XKEM), a development stage pharmaceutical company
based in New Brunswick, New Jersey. Prior to joining Xechem, Mr. Becker served
as a management consultant to a number of public and private companies. Mr.
Becker is also a licensed (non-practicing) attorney who practiced law for
eighteen years in New York City, specializing in business reorganizations and
corporate restructurings, including ten years with Kaye, Scholer, Fierman, Hays
& Handler, LLP. He also has been associated with Skadden, Arps and Milbank,
Tweed, Hadley & McCloy, LLP. Mr. Becker graduated MAGNA CUM LAUDE from Tufts
University in 1981 and received his law degree from the University of Michigan
Law School in 1984.

<Page>

JAMES K.T. LU (Class 3 Director). Mr. Lu has been a director since February
1989, Chairman of the Board, Chief Executive Officer and Secretary since March
1, 1990, and President since July 1991. As of April 1, 2002, Mr. Lu became
Co-Chairman and Co-Chief Executive Officer.

FRED U. ODAKA (Class 1 Director). Mr. Odaka has been our Chief Financial Officer
since September 2000. From December 1998 to September 2000 Mr. Odaka was a
consultant to Diamond Entertainment Corporation and was our "acting" Chief
Financial Officer. Mr. Odaka received his Bachelor of Science degree in finance
from Fresno State College, Fresno, California.

Under our certificate of incorporation, our board of directors is divided into
three (3) classes, with each class to be elected by the shareholders every three
years.

All directors hold office for terms up to three (3) years and until the next
annual meeting of stockholders scheduled to vote on such class of directors and
the election and qualification of their respective successors. Our board
presently consists of five directors and our directors were elected at the March
2005 annual meeting of stockholders for up to three-year terms. None of our
directors have resigned or declined to stand for re-election due to a
disagreement on any matter relating to our operations, policies or practices.
Officers are elected annually by our board of directors and, subject to existing
employment agreements, serve at the discretion of our board.

BOARD COMMITTEES

The Board of Directors does not currently maintain an Audit Committee or a
Compensation Committee but plans to appoint an Audit Committee and a
Compensation Committee in the near future. During the fiscal year ended March
31, 2007, the Board of Directors held approximately five meetings.

EXECUTIVE COMPENSATION

The following table sets forth aggregate compensation earned by each former
Executive Officer for services rendered in all capacities during the year ended
March 31, 2007, 2006 and 2005.

Summary Compensation Table

Annual Compensation Long Term Compensation
--------------------------- -----------------------------------------------
Awards Payouts
--------------- -------------------------------
Securities All Other
Underlying LTIP Payouts Compensation
Name and Principal Position Year Salary ($) Bonus ($) Options (#) ($) ($)
- ----------------------------------------- -------- ------------- ------------ --------------- -------------- ----------------

James K.T. Lu (1) Former President, 2007 150,000 0 0 0 33,424
Co-Chief Executive Officer and Secretary 2006 150,000 0 0 0 45,366
2005 150,000 17,308 0 0 41,228

Jeffrey I. Schillen (2) 2007 150,000 0 0 0 13,262
Former Co-CEO, Executive Vice 2006 150,000 0 0 0 23,462
President of Sales and Marketing 2005 150,000 13,846 0 0 26,001

<Page>

(1) Prior to the merger on May 4, 2007, Mr. Lu resigned from his positions with
the Company on April 26, 2007 as Co-CEO, President and Co-Chairman and was
concurrently appointed as Director. Mr. Lu's annual salary was $150,000 during
the fiscal year ended March 31, 2007, 2006 and 2005. During the fiscal years
ended March 31, 2007, 2006 and 2005, Mr. Lu was paid salaries totaling $0.00,
$112,500 and $150,000, respectively. He elected to defer a portion of his salary
for the years ended March 31, 2006 and 2004. In November 2006, Mr. Lu entered
into a Waiver of Debts Agreement with the Company and under such agreement Mr.
Lu waived all salaries owed to him by the Company totaling approximately
$449,000.

(2) Prior to the merger on May 4, 2007, Mr. Schillen resigned from his positions
with the Company on April 26, 2007 as Executive Vice President - Sales and
Marketing, Co-CEO and Co-Chairman. Mr. Schillen's annual salary was $150,000
during the fiscal years ended March 31, 2007, 2006 and 2005. During the fiscal
years ended March 31, 2007, 2006 and 2005, Mr. Schillen was paid salaries
totaling $0.00, $112,500 and $120,000. respectively. He elected to defer a
portion of his salary for the years ended March 31, 2006, 2005 and 2004. In
January 2007, Mr. Schillen, entered into a Waiver of Debts Agreement with the
Company and under such agreement Mr. Schillen waived all salaries owed to him by
the Company totaling approximately $588,000.

OPTION/SAR GRANTS (PRE-REVERSE STOCK SPLIT SHARES)

The following table sets forth certain information with respect to the options
granted and canceled during the year ended March 31, 2007, 2006 and 2005, for
the persons named in the Summary Compensation Table (the "Named Executive
Officers"):

Number of Percent of Total
Securities Options/SARs
Underlying Granted to
Options/SARs Employees in Exercise or Base
Name Year Granted (Canceled) Fiscal Year Price ($/Sh) Expiration Date
- ----------------------------------------------------------------------------------------------------------------------------

James K. T Lu 2007 (14,500,000) n/a $0.006 11/15/06
Jeffrey I. Schillen 2007 36,000,000 100% $0.010 1/31/17

James K.T. Lu 2006 25,000,000 43% $0.007 6/15/15
Jeffrey I. Schillen 2006 12,150,000 21% $0.007 6/15/15

James K.T. Lu 2005 (600,000) n/a $0.005 4/22/04
James K.T. Lu 2005 (3,500,000) n/a $0.005 5/24/04
James K.T. Lu 2005 (20,000,000) n/a $0.006 7/23/04
James K.T. Lu 2005 (3,000,000) n/a $0.005 3/31/05

Jeffrey I. Schillen 2005 (400,000) n/a $0.005 4/22/04
Jeffrey I. Schillen 2005 (1,000,000) n/a $0.005 5/24/04
Jeffrey I. Schillen 2005 (10,000,000) n/a $0.006 7/23/04
Jeffrey I. Schillen 2005 (750,000) n/a $0.005 3/31/05

<Page>

AGGREGATE OPTION/SAR EXERCISED IN LAST FISCAL YEAR AND FISCAL YEAR-END
OPTION/SAR VALUES (Pre-Reverse Stock Split Shares)

The following table sets forth certain information with respect to options
exercised during the fiscal year ended March 31, 2007 by the Named Executive
Officers and with respect to unexercised options held by such persons at March
31, 2007

Number of Securities Underlying Value of Unexercised
Shares Unexercised Options/SARs In-the-Money Options/SARs
Acquired On Value At FY-End (#) at FY-End ($)
Name Exercise (#) Realized ($) Exercisable Unexercisable Exercisable Unexercisable
- ----------------------------------------------------------------------------------------------------------------------------------

James K.T. Lu 0 0 16,666,667 8,333,333 $161,111 $80,556
Jeffrey I. 0 0 44,100,000 4,050,000 $426,300 $39,150
Schillen

EMPLOYMENT AGREEMENTS

In 1991, we entered into employment agreement with each of Messrs. Lu and
Schillen for annual compensation of $150,000 and $90,000, respectively; both
provide for annual adjustments in accordance with the consumer price index.
However, effective fiscal years 1996 and 2003, Mr. Schillen's annual
compensation was increased to $120,000 and $150,000, respectively. Consequently,
contracted salary levels were at $150,000 for Mr. Lu and Mr. Schillen. Both
employment agreements were extended in July 2000 for a period of five years and
such agreements terminated on December 31, 2005. During the year ended March 31,
2007, both Mr. Lu and Mr. Schillen agreed to waive all salaries and wages owed
to them for the current fiscal year including all prior years. In November 2006
and January 2007, Mr. Lu and Mr. Schillen entered into a Waiver of Debt
Agreement, respectively, whereby Mr. Lu and Mr. Schillen waived approximately
$449,000 and $588,000, respectively, in accrued salaries and wages. See "Summary
Compensation Table" above, and the notes thereto.

COMPENSATION OF DIRECTORS

The Company's Directors are not currently compensated for attendance at Board of
Directors meetings.

None

CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

On June 16, 2005, the Board of Directors of the Company approved the granting of
58,100,000 pre-split options to purchase the Company's common stock under the
Incentive Plan of the 2005 Equity Compensation Program to the select employees,
officers, directors and a consultant of the Company expiring no later than 10
years from the date the options were granted. The effective date of such options
being granted was June 16, 2005, at an exercise price of $.007 per share. Such
stock options granted vest in three annual installments commencing one year
after the date of grant. Of such options granted, James Lu, the President,
Jeffrey Schillen the Executive Vice President and Fred Odaka, Chief Financial
Officer of the Company were granted options to purchase 25,000,000, 12,150,000
and 5,000,000 pre-split shares, respectively, and 5,000,000 and 2,500,000
pre-split options were granted to Murray Scott and Jerry Lan, respectively, who
are Directors of the Company. The remaining balance of 7,450,000 pre-split
options was granted to six employees and one consultant of the Company. During
years ended March 31, 2007 and 2006 three employees and one consultant
terminated employment with the Company and an aggregate of 3,600,000 pre-split
of such options granted were canceled. The Company claims exemption from
registration of such issuance based on Section 4(2) of the Securities Act of
1933, as amended, inasmuch as the transaction was a non-public offering and sale
of securities.

<Page>

EMPLOYEE COMPENSATION

We do not yet have a compensation committee that approves or offers
recommendations on compensation for our employees.

LEGAL PROCEEDINGS

None

PROPOSAL I

ACTION TO CHANGE THE COMPANY NAME FROM DIAMOND ENTERTAINMENT CORPORATION TO RX
FOR AFRICA, INC.

The holders of a majority of the shares of our outstanding common stock
approved in writing an amendment to our Certificate of Incorporation to change
the company name from Diamond Entertainment Corporation to Rx for Africa, Inc.
The Company's new Symbol will be determined at the time the name change becomes
affective. The name change action was taken to reflect the Company's new
business which was a result of the acquisition of Rx for Africa, Inc by Diamond
Entertainment Acquisition, Corp. a wholly owned subsidiary of the Company.

PROPOSAL II

THE APPOINTMENT OF BERNSTEIN & PINCHUK, LLP AS AUDITORS FOR DIAMOND
ENTERTAINMENT, CORP.

The Board of Directors of the Company has selected Bernstein & Pinchuk,
LLP to audit the consolidated financial statements of the Company and its
subsidiaries for the fiscal year ending March 31, 2007. Bernstein & Pinchuk, LLP
has served in this capacity since May 25, 2007.

CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL
DISCLOSURE

A Form 8-K was filed on May 25, 2007, reporting a change in accounting firms.

On May 25, 2007, the Diamond Entertainment Corporation changed its principal
independent accountants from PMB + Helin Donovan Co, LLP, 50 Francisco Street,
Suite 120, San Francisco, CA 94133 to Bernstein & Pinchuk, LLP, 7 Penn Plaza,
Suite 830, New York, NY 10001. PMB + Helin Donovan Co, LLP was dismissed and the
decision to change accountants was approved by the Board of Directors and audit
committee.

The reports of PMB + Helin Donovan, Co, LLP on the financial statements for the
past two years ended March 31, 2005 and 2006 and the current year through the
third quarter ended December 31, 2006, and through the date of dismissal of May
25, 2007, contained no adverse opinions or disclaimers or were qualified as to
audit review scope, or accounting principles, except that a going concern
uncertainty was included in such reports.

<Page>

During the Diamond Entertainment Corporation's past two years ended March 31,
2005 and 2006 and through the third quarter ended December 31, 2006, and through
the date of dismissal of May 25, 2007, there were no disagreements with PMB +
Healin Donovan Co, LLP on any matter of accounting principles or practices,
financial statement disclosure, or auditing review scope or procedures, which
disagreements, if not resolved to the satisfaction of the former accountant,
would have caused it to make a reference to the subject matter of the
disagreements in connection with its report.

During the Diamond Entertainment, Corp.'s two most recent fiscal years ended
March 31, 2006 and 2005 and the current year through the third quarter ended
December 31, 2006, and through the date of dismissal of May 25, 2007, Diamond
Entertainment Corporation. did not consult with Bernstein & Pinchuk LLP
regarding any of the matters or events set forth in Item 304 (a)(2) of
Regulations S-B.

OTHER MATTERS

The Board of Directors of the Company is not aware that any matter other than
those described in this Information Statement is to be presented for the consent
of the shareholders.

ADDITIONAL INFORMATION

We are subject to the informational requirements of the Securities Exchange Act
of 1934 and in accordance with the requirements thereof, file reports, proxy
statements and other information with the Securities and Exchange Commission
("SEC"). Copies of these reports, proxy statements and other information can be
obtained at the SEC's public reference facilities at Judiciary Plaza, Room 1024,
450 Fifth Street, N.W., Washington, D.C., 20549. Additionally, these filings may
be viewed at the SEC's website at http://www.sec.gov.

DISTRIBUTION OF INFORMATION STATEMENT

The cost of distributing this Information Statement has been borne by us and
certain shareholders that consented to the action taken herein. The distribution
will be made by mail.

Pursuant to the requirements of the Exchange Act of 1934, as amended, the
Registrant has duly caused this Information Statement to be signed on its behalf
by the undersigned hereunto authorized.

By Order of the Board of Directors

/s/ Dr. Mulugetta Bezzabeth
-----------------------------------
Dr. Mulugetta Bezzabeth
Director

July 25, 2007
City of Industry, California